Physician profile
Grace Roberts
NPI 1225834666
$808.71
in general payments reported to CMS, 2019-2025
14 companies · $809 in 2025
The $809 reported for 2025 was more than what 86% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2025: $809.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $809.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $808.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $194.43 | 2025 | Airsupra, Farxiga, Breztri |
| Neurocrine Biosciences, INC. | $155.66 | 2025 | |
| Astellas Pharma US INC | $93.85 | 2025 | Veozah |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $60.84 | 2025 | Caplyta |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $47.68 | 2025 | Xifaxan |
| Glaxosmithkline, LLC. | $43.97 | 2025 | Shingrix, Trelegy Ellipta |
| Exact Sciences Corporation | $37.42 | 2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Pfizer INC. | $37.39 | 2025 | |
| Vertex Pharmaceuticals Incorporated | $29.66 | 2025 | |
| Otsuka America Pharmaceutical, INC. | $23.61 | 2025 | Rexulti |
| Novo Nordisk INC | $23.05 | 2025 | Wegovy |
| Takeda Pharmaceuticals U.S.A., INC. | $21.94 | 2025 | Trintellix |
| Seqirus USA INC | $20.34 | 2025 | Fluad, Flucelvax |
| Azurity Pharmaceuticals, INC. | $18.87 | 2025 | Edarbi |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Grace Roberts listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.